New Zealand markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
285.28+5.15 (+1.84%)
At close: 04:00PM EDT
285.28 0.00 (0.00%)
After hours: 04:50PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 8.11B
Enterprise value 7.91B
Trailing P/E N/A
Forward P/E 25.64
PEG ratio (5-yr expected) 1.07
Price/sales (ttm)3.12
Price/book (mrq)0.93
Enterprise value/revenue 2.96
Enterprise value/EBITDA -12.08

Trading information

Stock price history

Beta (5Y monthly) 0.88
52-week change 3-34.57%
S&P500 52-week change 325.01%
52-week high 3473.50
52-week low 3261.59
50-day moving average 3327.38
200-day moving average 3339.28

Share statistics

Avg vol (3-month) 3210.42k
Avg vol (10-day) 3234.98k
Shares outstanding 523.42M
Implied shares outstanding 628.52M
Float 819.96M
% held by insiders 115.24%
% held by institutions 181.71%
Shares short (28 Mar 2024) 4564.75k
Short ratio (28 Mar 2024) 43.22
Short % of float (28 Mar 2024) 43.17%
Short % of shares outstanding (28 Mar 2024) 41.98%
Shares short (prior month 29 Feb 2024) 4503.41k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 308 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin -23.86%
Operating margin (ttm)14.24%

Management effectiveness

Return on assets (ttm)1.77%
Return on equity (ttm)-6.94%

Income statement

Revenue (ttm)2.67B
Revenue per share (ttm)91.45
Quarterly revenue growth (yoy)-6.70%
Gross profit (ttm)N/A
Net income avi to common (ttm)-637.32M
Diluted EPS (ttm)-21.82
Quarterly earnings growth (yoy)-57.80%

Balance sheet

Total cash (mrq)1.61B
Total cash per share (mrq)56.35
Total debt (mrq)1.41B
Total debt/equity (mrq)16.08%
Current ratio (mrq)5.83
Book value per share (mrq)306.51

Cash flow statement

Operating cash flow (ttm)374.9M
Levered free cash flow (ttm)170.82M